Zoltán Gulyás is a senior field applications scientist for the TFF systems and filters at Repligen, providing technical support to customers in Western and Southern Europe. Gulyás has an MSc degree in ...
The antibody-drug conjugate landscape is facing a critical inflection point. As it stands, manufacturing complexity could pose a threat to future innovation, despite the unmatched market demand. With ...
Antibody-drug conjugates (ADCs) constitute a rapidly evolving class of targeted oncology therapeutics that couple tumor-selective antibodies with highly potent cytotoxins. At the 16th Annual World ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results